Allergan (NYSE: AGN) said today its Allergan Sales subsidiary will acquire medical device developer Keller Medical for an undisclosed amount.
Keller Medical is a privately held medical device company which developed the Keller Funnel, a cone-shaped, lubricated plastic funnel designed to reduce surgeon and patient contact during breast augmentation or reconstruction procedures. The device was originally launched in 2009, with a next-gen version released in 2014.
“The purchase of Keller Medical demonstrates Allergan’s ongoing commitment to excellence in breast augmentation and reconstruction surgery. The Keller Funnel has become an innovative component to deliver the highest level of care for my cosmetic and reconstructive breast implant patients,” Dr. Louis Bucky of the University of Pennsylvania School of Medicine said in a prepared statement.
The Keller Funnel is used to assist in breast augmentation or reconstruction surgeries by guiding silicone gel implants into the surgical pocket, reducing the necessity of touching the implant to reduce foreign bodies and bacteria.
“Allergan is focused on providing technologies and products to help our surgeon customers improve procedures and Keller Funnel is that product for breast augmentation and reconstruction procedures. The Keller Funnel was developed and designed by pioneering surgeons to improve breast implantation, and reduce the risks of implant contamination during procedures. This is a natural complement to our world-class plastic surgery and regenerative medicine business, and marketing this innovative device further enhances our commitment to our customers and patients,” medical aesthetics division senior VP David Moatazedi said in a press release.
In April, Allergan said it won FDA clearance for its TrueTear intranasal tear neurostimulator designed to stimulate tear production, touting it as the 1st of its kind.
The TrueTear device is designed to be inserted into the nasal cavity to induce the production of tears, the company said.